Australia’s Viral Vector Manufacturing Facility has received a Therapeutic Goods Administration manufacturing license for its Sydney site, allowing the company to produce specified viral vectors under good manufacturing practice standards.
The regulator’s public database lists license MI-2026-LI-00389-1 for Viral Vector Manufacturing Facility Pty Ltd, with an issue date of September 3, 2026. The licensed site is at the Westmead Health and Innovation Precinct in New South Wales.
VVMF announced the approval on September 10, describing it as a step toward providing local manufacturing services for developers of cell and gene therapies in Australia and across Asia Pacific. The company’s official announcement said the license followed an assessment of the facility, its quality systems, manufacturing operations and operational capability.
License covers manufacturing and quality control
The license authorizes the GMP manufacture of replication-incompetent viral vectors made using recombinant technology. It covers production as sterile active pharmaceutical ingredients or sterile medicinal products, along with associated quality-control testing.
Viral vectors carry genetic material into cells and are used in the development of gene therapies and genetically modified cell therapies. The TGA authorization applies to manufacturing activities at VVMF’s facility; it is not an approval for any specific therapy.
The TGA’s manufacturer-search guidance explains that Australian manufacturers are approved for specific steps of production and that current license details can be checked through the regulator’s eBusiness Services database. TNGlobal verified VVMF’s name, Westmead address, issue date and license number in that database.
BiotechDispatch independently reported the license and the authorized manufacturing scope. VVMF calls itself Australia’s first viral vector contract development and manufacturing organization, although the company did not publish a comparison of all Australian facilities supporting that claim.
Westmead site targets an Asia-Pacific manufacturing gap
VVMF said the Westmead operation can provide process development, analytical development, GMP manufacturing and quality-control testing. It is pitching those services to biotechnology companies, researchers and therapy developers seeking a regional alternative to overseas viral vector suppliers.
The company did not disclose the site’s current production capacity, signed customer programs, pricing or expected revenue from the license. It also did not say when the first client batch would begin manufacturing or whether the facility is equipped for commercial-scale output as well as clinical programs.
VVMF has been building its technical platform through an agreement with UK-based cell and gene therapy manufacturer OXB. Under a five-year licensing and option agreement announced in March, VVMF obtained a worldwide, non-exclusive license to OXB’s adeno-associated virus platform and an option covering its lentiviral vector platform.
OXB said at the time that the agreement was intended to accelerate VVMF’s operational and commercial readiness, with a focus on demand from Asia Pacific. The UK company disclosed a low single-digit million license fee but did not provide the currency or any targets for future payments tied to use of the platforms.
Approval adds local capability without guaranteeing demand
The TGA license gives VVMF a regulatory basis to perform the manufacturing steps listed in its approval. Customer uptake will still depend on therapy pipelines, technical transfers, production performance and the economics of using an Australian supplier.
VVMF said local manufacturing could reduce reliance on overseas capacity and support programs from early development through clinical translation. The announcement did not quantify expected time savings, costs or the number of programs the facility could handle.
For developers in Australia and the wider region, the new license adds a domestic option for specialized manufacturing and testing. Its commercial impact will become clearer as VVMF discloses client projects, batch activity and the scale at which the Westmead site operates.
Merck expands biosafety testing laboratory in Singapore to strengthen services across Asia Pacific